ADIPOTIDE INJECTOR PEN 3ML 10MG

Adipotide: The Prohibitin‑Targeting “Hunter‑Killer” Peptidomimetic for White‑Fat Ablation and Metabolic Research

In the evolving domain of vascular‑targeted metabolic research, Adipotide (also referenced in scientific and regulatory contexts as prohibitin‑targeting peptide 1 / TP01) is a chimeric, ligand‑directed peptidomimetic designed to selectively target the vasculature of white adipose tissue (WAT) rather than modulating appetite hormones or classic lipolysis pathways. Its research interest stems from a distinctive mechanism: binding to prohibitin expressed in white‑fat vasculature, followed by receptor‑mediated internalization and delivery of a mitochondria‑disrupting, pro‑apoptotic motif that promotes apoptosis in the targeted cells ultimately leading to ablation and resorption of white fat in animal models.

Unlike conventional anti‑obesity approaches focused on CNS appetite suppression or generalized metabolic stimulation, Adipotide is frequently framed as a vascular “zip‑code” strategy aiming to home specifically to adipose‑supporting blood vessels and disrupt the local support network of unhealthy fat. In nonhuman primate studies, treatment was associated with rapid weight loss, imaging‑confirmed reduction in white adipose tissue, and improved insulin resistance, alongside predictable, reversible renal proximal tubule effects that are central to its safety interpretation.

Adipotide remains investigational and is not FDA‑approved as a therapy for obesity (or any other indication). Any outcomes below reflect controlled research findings and should be interpreted in that context.

Mechanism Overview: How Adipotide Targets White Fat at the Vascular Level

Adipotide is constructed from two functional domains:

1. Fat‑homing / targeting motif: CKGGRAKDC

2. Pro‑apoptotic payload: two repeats of (KLAKLAK) with a GG linker, commonly described with a D‑enantiomer pro‑apoptotic segment to enhance stability and biological effect.

The NCI Drug Dictionary describes prohibitin‑targeting peptide 1 (TP01) as a chimeric peptide consisting of a fat‑targeting motif, two repeats of the pro‑apoptotic motif, and a GG linker; it binds prohibitin in white adipose vasculature and, upon internalization, triggers apoptosis leading to ablation of white fat.

Foundational work established prohibitin as a vascular marker of adipose tissue and showed that directing a pro‑apoptotic peptide to prohibitin in adipose vasculature can drive white‑fat ablation and rapid obesity reversal in preclinical models.

Five Research‑Backed Benefits and Study‑Observed Effects

1) Selective White‑Fat Vasculature Targeting and White‑Fat Ablation in Foundational Preclinical Models

A cornerstone of Adipotide’s scientific rationale is the identification of CKGGRAKDC as a motif that associates with prohibitin and enables adipose‑selective vascular targeting. In the seminal Nature Medicine report, targeting a pro‑apoptotic peptide to prohibitin in adipose vasculature caused ablation of white fat, with resorption of established WAT and normalization of metabolism reported as part of rapid obesity reversal in the tested models.

Why this matters for metabolic research: It provides a mechanistically distinct tool for exploring how adipose vasculature regulates fat mass and how vascular‑niche disruption influences systemic metabolic endpoints.

2) Significant Weight and Fat‑Mass Reduction in Obese Rodent Models, With Measurable Energy‑Intake Effects

A mechanistic rodent study (published on PMC) describes a pro‑apoptotic peptide targeting white‑fat endothelium/vasculature and reports that, when administered over weeks, it reduced body weight and fat mass in ob/ob mice and diet‑induced obese mice without producing evidence consistent with abnormal fat absorption.

Importantly, this work also examined why weight changed and reported that cumulative energy intake decreased in treated obese mice and that there was no conditioned taste aversion signal like a toxin control supporting interpretation of a satiety/energy‑balance shift rather than simple malaise in that model.

Why this matters for study design: In Adipotide research, weight loss is often accompanied by behavioral/energy intake changes, so rigorous interpretation benefits from tracking food intake, energy expenditure, and body composition in parallel.

3) Rapid, Imaging‑Confirmed Reduction of Visceral and Subcutaneous White Fat in Obese Nonhuman Primates

The most widely cited translational evidence comes from a Science Translational Medicine study (available on PMC) evaluating Adipotide in obese Old World monkeys. The authors report that treatment induced targeted apoptosis within blood vessels of white adipose tissue and produced dose‑dependent decreases in body weight, BMI, and abdominal circumference in obese rhesus macaques.

Within the same primate study, MRI‑based quantification showed decreases in abdominal white adipose tissue volumeover the treatment interval, with visual confirmation of reductions in both visceral and subcutaneous abdominal WAT.

Why this matters: This moves beyond scale weight to demonstrate fat‑mass compartment change—a key translational benchmark for obesity research.

4) Improved Insulin Resistance Markers in Obese Monkeys Without Major Deterioration in Glucose Handling

In the same primate paper, treated animals showed improvements consistent with better insulin sensitivity. The authors describe reduced insulin responses during glucose tolerance testing and report a notable decrease in insulin area‑under‑the‑curve in treated animals compared with controls interpreted as improved insulin sensitivity.

Why it matters: This supports the hypothesis that targeted reduction of white adipose tissue particularly visceral stores can improve insulin resistance physiology in a primate model with closer relevance to human metabolic syndrome than many rodent models.

5) Defined Safety Signal in Primates: Predictable, Reversible Renal Proximal Tubule Effects

Adipotide’s research profile cannot be separated from its safety observations. The primate study explicitly notes that, at experimentally determined doses, monkeys displayed predictable and reversible changes in renal proximal tubule function.

In the discussion, the authors characterize the primary side effect as generally mild and reversible renal toxicity, with described laboratory findings including electrolyte and urinary changes consistent with altered proximal tubular function/tubular injury, resolving during recovery.

Why this matters: Any translational interpretation or future analog development must account for renal handling/catabolism and the exposure window in which benefits and toxicity co‑emerge.

nterpretation Considerations: Vascular Ablation vs. Food‑Intake Mediation

Across models, investigators observed that weight loss can occur alongside reduced food intake. The primate paper reports weight loss concurrent with decreased food intake and notes that lean monkeys receiving a therapeutic dose did not lose weight suggesting a context‑dependent mechanism in primates.

A published comment on the primate work (Sci Transl Med) argues that observed weight loss effects may reflect a direct effect on food consumption, underscoring that appetite/feeding dynamics are not ancillary variables but central to interpretation.

Rodent mechanistic work aligns with the importance of this dimension by documenting reductions in energy intake in treated obese animals and evaluating aversion/toxicity‑like confounding.

Scientific Studies and Links